How Wegovy Works Compared to Other Weight Loss Drugs
Wegovy (semaglutide) is a GLP-1 receptor agonist that mimics the hormone GLP-1 to slow gastric emptying, reduce appetite, and regulate blood sugar, leading to 15-20% average weight loss in trials.[1] Unlike older drugs like phentermine (an appetite suppressant) or orlistat (a fat absorption blocker), Wegovy targets multiple gut-brain pathways for sustained effects. It differs from dual agonists like tirzepatide (Zepbound/Mounjaro), which also activates GIP receptors for potentially greater weight loss (up to 22%).[2]
What Sets Wegovy Apart from Ozempic and Saxenda
Wegovy uses the same active ingredient as Ozempic (semaglutide) but at higher weekly doses (2.4 mg vs. 0.5-2 mg) optimized for weight loss, not just diabetes.[1] Saxenda (liraglutide), another GLP-1 drug from Novo Nordisk, requires daily injections and yields less weight loss (5-10%). Wegovy's once-weekly pen simplifies adherence.[3]
Why Wegovy's Approval and Dosing Stand Out
FDA-approved specifically for chronic weight management in 2021 (after Ozempic's 2017 diabetes nod), Wegovy targets adults with BMI ≥30 or ≥27 with comorbidities.[1] It ramps up gradually (0.25 mg to 2.4 mg over 16 weeks) to minimize nausea, unlike abrupt starts with generics like phentermine.[4]
Wegovy's Weight Loss Results vs. Competitors
Clinical trials show Wegovy users lose 15% body weight over 68 weeks, outperforming liraglutide (8%) and placebo (2.4%).[1] It edges out single GLP-1s but trails tirzepatide's 20-22% in head-to-head data.[2] Long-term data (STEP trials) confirm durability up to 2 years, rare for older drugs.[5]
| Drug | Mechanism | Avg. Weight Loss | Dosing | FDA Approval Year (Weight Loss) |
|------|-----------|------------------|--------|---------------------------------|
| Wegovy | GLP-1 only | 15-20% | Weekly injection | 2021 |
| Zepbound | GLP-1 + GIP | 20-22% | Weekly injection | 2023 |
| Saxenda | GLP-1 only | 5-10% | Daily injection | 2014 |
| Phentermine | Appetite suppressant | 5-10% (short-term) | Daily pill | 1959 |
| Qsymia | Phentermine + topiramate | 8-10% | Daily pill | 2012 |
Side Effects and Safety Differences
Common issues like nausea, diarrhea, and vomiting affect 40-50% initially but fade; gallbladder risks rise with rapid loss.[1] Unlike stimulants (phentermine), no cardiovascular stimulation. Rare pancreatitis or thyroid tumors in rodents, but human risk low.[6] Dual agonists like tirzepatide report similar GI effects but higher muscle loss concerns.[2]
Cost and Access Compared to Alternatives
Wegovy lists at $1,300-$1,700/month without insurance, comparable to Zepbound but pricier than generics ($50-200/month).[7] Novo Nordisk cards cap copays at $25 for eligible patients. Supply shortages persist due to demand, unlike pill-based options.[8]
Patent Timeline and Biosimilar Threats
Novo Nordisk holds patents on semaglutide until 2032 in the US, with formulation patents possibly to 2036.[9]DrugPatentWatch.com. Challenges from Hims & Hers and others target earlier expiry, but no generics until late 2020s. Eli Lilly's tirzepatide patents extend to 2036.[9]
Sources:
[1] Novo Nordisk STEP trials (NEJM 2021)
[2] SURMOUNT trials (NEJM 2023)
[3] FDA labels
[4] Novo Nordisk prescribing info
[5] JAMA 2022 extension study
[6] FDA safety updates
[7] GoodRx pricing data
[8] FDA shortage list
[9] DrugPatentWatch.com